Ryvu Therapeutics S.A. (WSE:RVU)
28.35
+0.25 (0.89%)
Oct 3, 2025, 5:00 PM CET
Ryvu Therapeutics Revenue
Ryvu Therapeutics had revenue of 95.03M PLN in the quarter ending June 30, 2025, with 17.44% growth. This brings the company's revenue in the last twelve months to 130.10M, down -32.25% year-over-year. In the year 2024, Ryvu Therapeutics had annual revenue of 101.96M with 51.51% growth.
Revenue (ttm)
130.10M
Revenue Growth
-32.25%
P/S Ratio
4.00
Revenue / Employee
396.63K
Employees
328
Market Cap
520.38M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 101.96M | 34.67M | 51.51% |
Dec 31, 2023 | 67.30M | -1.14M | -1.67% |
Dec 31, 2022 | 68.44M | 33.02M | 93.25% |
Dec 31, 2021 | 35.41M | -1.54M | -4.16% |
Dec 31, 2020 | 36.95M | 3.23M | 9.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Diagnostyka | 2.17B |
NEUCA | 13.04B |
Synektik Spólka Akcyjna | 623.20M |
Voxel | 560.38M |
Celon Pharma | 206.22M |
Selvita | 373.90M |
Centrum Medyczne ENEL-MED | 789.78M |
Scope Fluidics | 720.00K |